Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 14/20 | 0.47 |
| ▸ | MMP1 | P03956 | 4/20 | 0.41 |
| ▸ | NPPA | P01160 | 2/20 | 0.40 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.39 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6811310 | 1.00 | MME (0.47) | MMEMMP1NPPACYP26A1ITGB1 | |
| SCHEMBL6806967 | 0.93 | MME (0.51) | MMEMMP1NPPAITGB1ITGA4 | |
| SCHEMBL8337080 | 0.92 | MME (0.39) | MMEMMP1NPPACYP26A1ITGB1 | |
| SCHEMBL8332506 | 0.86 | MME (0.42) | MMEMMP1NPPAITGB1ITGA4 | |
| SCHEMBL6806867 | 0.76 | MME (0.64) | MMEMMP1NPPAITGB1ITGA4 | |
| SCHEMBL6806869 | 0.76 | MME (0.64) | MMEMMP1NPPAITGB1ITGA4 | |
| SCHEMBL6807360 | 0.73 | MME (0.73) | MMEMMP1NPPAITGB1ITGA4 | |
| SCHEMBL6808018 | 0.71 | MME (0.68) | MMENPPAITGB1ITGA4ITGB7 | |
| SCHEMBL6255996 | 0.71 | MME (0.73) | MMEMMP1NPPAITGB1ITGA4 | |
| SCHEMBL6938890 | 0.71 | MME (0.61) | MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138274-A1 | Cardiovascular disorders; hypotensive agents; endopeptidase inhibitor; sexual disorders | DACK KEVIN NEIL (GB) | 2004-07-15 | — | — | US | disclosed |
| WO-2004056787-A1 | CYCLOPENTYL GLUTARAMIDES AND THEIR USE AS NEUTRAL ENDOPEPTIDASE INHIBITORS | PFIZER LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138274-A1 | Cardiovascular disorders; hypotensive agents; endopeptidase inhibitor; sexual disorders | MME, ECE1, ECE2 | MME 1/4885MMP1 539/4885NPPA 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.